BNF 83 (British National Formulary)


85,73 81,43

Autor: Joint Formulary Committee
Edición: 83
Páginas: 1848
Año edición: March/2022
SKU: 9780857114341 Categoría:
The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.
The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.
Extensive content updates in the BNF 83 edition include:
New monographs for:
  • Acarizax® [house dust mite extract] for house dust mite allergic rhinitis or house dust mite allergic asthma
  • Adakveo® [crizanlizumab] for vaso-occlusive crises in sickle-cell disease
  • Adtralza® [tralokinumab] for atopic eczema
  • Bijuve® [estradiol with progesterone] for menopausal symptoms
  • Evrenzo® [roxadustat] for symptomatic anaemia associated with chronic kidney disease
  • Evrysdi® [risdiplam] for 5q spinal muscular atrophy
  • Kesimpta® [ofatumumab] for multiple sclerosis
  • Klisyri® [tirbanibulin] for actinic keratosis on face or scalp
  • Lagevrio® [molnupiravir] for COVID-19
  • Leqvio® [inclisiran] for primary hypercholesterolaemia or mixed dyslipidaemia
  • Lumykras® [sotorasib] for non-small cell lung cancer with KRAS G12C mutation
  • Ontozry® [cenobamate] for focal seizures with or without secondary generalisation
  • Orladeyo® [berotralstat] for hereditary angioedema
  • Pemazyre® [pemigatinib] for cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
  • Ponvory® [ponesimod] for multiple sclerosis
  • Rukobia® [fostemsavir] for HIV drug-resistant infection
  • Ryaltris® [mometasone furoate with olopatadine] for allergic rhinitis
  • Ryeqo® [relugolix with estradiol and norethisterone acetate] for uterine fibroids
  • Verquvo® [vericiguat] for chronic heart failure with reduced ejection fraction
  • Zibor® [bemiparin sodium] for prophylaxis of deep-vein thrombosis in general and orthopaedic surgery, and prevention of clotting in extracorporeal circuits
MHRA advice on:
  • Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use
  • Aflibercept (Eylea®) solution for intravitreal injection: higher risk of intraocular pressure increase with the pre-filled syringe
  • Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
  • CDK4/6 inhibitors: reports of interstitial lung disease and pneumonitis, including severe cases
  • Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years
  • Dapagliflozin (Forxiga®) 5mg should no longer be used for the treatment of type 1 Diabetes Mellitus
  • Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products
  • Oral retinoid medicines: temporary monitoring advice during coronavirus (COVID-19) pandemic
  • Tofacitinib (Xeljanz®): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors, and new measures to minimise risk
  • Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
  • Venetoclax (Venclyxto®): updated recommendations on tumour lysis syndrome (TLS) in chronic lymphocytic leukaemia (CLL) patients
  • Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist
Other significant changes include updated guidance on:
  • COVID-19 updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines
  • Advice on use of Dapagliflozin in renal impairment, including new indication for chronic kidney disease
  • Diabetic hyperglycaemic emergencies
  • Direct-acting oral anticoagulants
  • Emergency contraception
  • Malaria prophylaxis in-line with Public Health England recommendations
  • Management of acne
  • Management of acute coronary syndromes
  • Management of anaphylaxis
  • Management of secondary bacterial infection of common skin conditions
  • Management of nausea and vomiting during pregnancy
  • Prescribing in renal impairment
  • Rabies vaccine and post-exposure management
  • Recommended insulin regimens in type 1 diabetes
  • Tetanus vaccine and the use of immunoglobulin for tetanus infection and prophylaxis in-line with Public Health England recommendations
BNF 83 is an essential publication, it provides you with:
  • Up-to-date information on prescribing, dispensing, and administering medicines
  • Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
  • Information you know you can trust for quality, reliability, and independence
  • Everything you need at your fingertips, all in one book


No hay valoraciones aún.

Sé el primero en valorar “BNF 83 (British National Formulary)”

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Ir arriba